← board
CLCS
distress 4/10 · elevated risk$0.800%today-19% from 52w high
Revenue
pre-revenue
Liquidity
$0M
Runway
0.0 yrs
Shares 1y
0%
Price & events
-11.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+0.3%
1W
+22.2%
1M
-4.8%
3M
-11.1%
6M
+128.5%
1Y
+99900.0%
2Y
-57.9%
5Y
-60.0%
All
Overview
- Market Cap
- $54.36M
- Volume
- 0
- 52 Week Range
- $0.31 – $0.99
- Total Shares
- 67.95M
- % Held by Insiders
- 19.68%
- % Held by Institutions
- 0.00%
- Beta
- -194.37
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 67,945,856 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.